BridgeBio Pharma (BBIO) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
United Therapeutics (UTHR) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 16.8% versus a gain of 11.6%. Over five years, UTHR leads with a +186.5% price change compared with +92.2% for BBIO. United Therapeutics is the larger company by market cap ($23.63 billion vs $14.81 billion), about 1.6 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs +10.6%).
United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | UTHR |
|---|---|---|
| Share price | $76.03 | $554.73 |
| Market cap | $14.81B | $23.63B |
| 1-day change | -2.75% | -0.78% |
| YTD return | -0.60% | +13.85% |
| 1-year return | +11.63% | +16.83% |
| 5-year return | +92.24% | +186.47% |
| P/E ratio (TTM) | — | 20.94 |
| Forward P/E | — | 17.44 |
| EPS (TTM) | $-3.03 | $26.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $3.18B |
| Revenue growth (YoY) | +126.26% | +10.61% |
| Net income (latest FY) | $-732.94M | $1.33B |
| Gross margin | 95.82% | 87.92% |
| Operating margin | -104.25% | 46.89% |
| Net margin | -145.98% | 41.94% |
| 52-week high | $93.42 | $614.23 |
| 52-week low | $62.50 | $455.63 |
| Distance from 52-week high | -18.61% | -9.69% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +40.73% | +23.87% |
| Average volume | 2.67M | 702.78K |
| Shares outstanding | 194.80M | 42.59M |
| Employees | 1,081 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +10.61%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
BBIO vs UTHR FAQ
Which is bigger, BridgeBio Pharma or United Therapeutics?
United Therapeutics (UTHR) is larger, with a market capitalization of $23.63B compared with $14.81B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, BBIO or UTHR?
UTHR returned +16.83% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.